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Abstract
There are multiple uses for antibiotics during pregnancy: treatment of intercurrent bacterial
infections such as urinary or respiratory tract infections, maternal treatment to prevent fetal or
neonatal disease, prophylactic treatment for surgical procedures, and treatment of puerperal
infections. This report will summarize the current recommendations for the use of antibiotics
specifically to reduce the risk of preterm birth.
Introduction and context
Preterm delivery, the leading cause of perinatal morbid-
ity and mortality worldwide, occurs in 12–13% of births
in the US and 5–9% of births in many other developed
countries [1]. Spontaneous preterm labor and preterm
premature rupture of membranes together account for
80% of preterm births [2]. There is substantial evidence
that infection and inflammatory mediators are impli-
cated in the pathogenesis of preterm birth. Of all
premature births, 25% or more occur in women with
evidence of infection of the amniotic cavity [3].
Furthermore, proinflammatory cytokines, such as inter-
leukin-1-beta and tumor necrosis factor-alpha, have
been identified as mediators in the pathophysiology of
preterm labor [4]. Specific maternal bacterial infections
that have been shown to be associated with an increased
risk of preterm birth include urinary tract infection [5],
lower genital tract infection [6], and periodontal infec-
tion [7]. The specific pathophysiologic mechanisms by
which these infections cause preterm birth include direct
ascending infection of the placenta and fetus, transpla-
cental blood-borne infection, and systemic activation of
proinflammatory cytokines that activate prostaglandin
production.
There is no controversy about the treatment of sympto-
matic bacterial infections during pregnancy, such as
pyelonephritis, vaginitis, cervicitis, pneumococcal
pneumonia, or listeriosis. A high index of clinical
suspicion, the use of appropriate laboratory measures
to confirm the diagnosis and identify the specific
organism, and prompt treatment with appropriate
antibiotics will reduce maternal morbidity, forestall
preterm birth, and prevent fetal infections as in the
case of listeriosis. What is controversial is the extent to
which screening for and treatment of asymptomatic
infection or antibiotic treatment of asymptomatic
women at increased risk of preterm birth will reduce
the risk of preterm birth or otherwise decrease perinatal
morbidity.
In prescribing antibiotics (or any other drugs), for
whatever indication, to women who are pregnant,
physicians must keep in mind the potential untoward
effect on the developing embryo and fetus. This is
particularly important in the first 56 days of pregnancy,
when the developing embryo is at the greatest risk of
teratogenic effects of medications. If there is any doubt
about the safety of a medication, a reliable reference
should be consulted, such as that by Briggs et al. [8].
Recent advances
Asymptomatic bacteriuria
Screening for and antibiotic treatment of asymptomatic
bacteriuria during pregnancy are widely accepted as
means of preventing pyelonephritis and reducing the risk
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in the reduction of the risk of preterm birth is not entirely
clear. Screening for bacteriuria in prenatal patients is
advised. A meta-analysis by Devillé et al. [9], which
included 70 studies, found the urine dipstick method of
screening to be useful in excluding the presence of
infection, especially in pregnant women. However, the
rapid tests are less reliable in detecting infection and their
use should not replace urine culture for detecting
asymptomatic bacteriuria [9].
Bacterial vaginosis
Bacterial vaginosis (BV) is characterized by an over-
growth of a variety of anaerobic organisms, including
Garderella vaginalis, Mycoplasma hominis, Mobiluncus
species, Atopobium vaginae, and other organisms, and an
associated reduction in normal vaginal Lactobacillus
species [10]. A recent meta-analysis of 15 controlled
trials, which included 5,888 women, found that anti-
biotic treatment was highly effective in eradicating BV in
pregnancy [11]. However, a meta-analysis of seven recent
randomized controlled trials of screening and treatment
of pregnant women who were asymptomatic for BV
evidence found that screening and treatment of pregnant
women for BV did not result in a reduction in preterm
birth. Also, there was concern about the potential for
unintended harm from the treatment [12]. That study
resulted in the recommendation by the US Preventive
Services Task Force that current evidence is insufficient to
support a policy of screening for BV in pregnant women
at high risk for preterm delivery [13]. The use of
probiotics (live organisms, especially Lactobacillus spe-
cies) has been shown to be effective in treating BV, but
evidence that probiotic treatment reduces the risk of
preterm birth is lacking [14].
Antibiotic treatment for patients in preterm labor
Although the role of inflammation in the pathophysiol-
ogy of spontaneous preterm birth is well documented,
there is no evidence that the routine use of antibiotics in
the management of patients with preterm labor has
reduced the incidence of preterm birth. The most
important study showing that lack of effectiveness of
antibiotic therapy for preterm labor was the ORACLE II
randomized controlled trial [15]. Women with intact
membranes and in spontaneous premature labor (n =
6,295) were randomly assigned to treatment with
various combinations of erythromycin, amoxicillin,
and clavulanic acid and a placebo four times daily for
10 days. Although antibiotic treatment was associated
with a lower occurrence of maternal infection, none of
the antibiotic regimens were associated with a lower
incidence of preterm birth. A meta-analysis by King and
Flenady [16] of 11 controlled trials, which included the
data from the ORACLE II trial, confirmed these findings.
A follow-up study of 3,196 children from the ORACLE II
trial at 7 years of age found that those who had received
erythromycin either alone or in combination with
amoxiclav were significantly more likely to have devel-
oped cerebral palsy [17]. In an evaluation of this study,
Faculty of 1000 member Michael Marsh raised
the possibility that the use of antibiotics might mask
the signs of intrauterine infection thereby leading to the
delayed delivery of an affected infant [18].
A recent meta-analysis of 17 controlled trials of the use of
antibiotics in patients at risk of premature birth because
of abnormal vaginal flora, previous preterm birth, or
positive fetal fibronectin, found that there was no
association between antibiotic treatment and reduction
in preterm birth irrespective of the criteria used to assess
risk, the antimicrobial agent administered, or gestational
age at the time of treatment [19]. These data would be in
accord with the recommendation of the American
College of Obstetricians and Gynecologists (ACOG)
that women in preterm labor should not be treated with
antibiotics for the sole purpose of preventing preterm
delivery [20].
At least two recent trials have found that preconception
use of antibiotics to treat patients at increased risk of
preterm birth has not been effective in reducing the
subsequent risk of delivering a preterm infant for these
patients, and in some instances, the treatment actually
increased the risk of subsequent preterm birth [21,22]. In
an evaluation of the study by Tita et al. [22], Faculty of
1000 member Bryan Larsen suggested that the destruc-
tion of bacteria by antibiotics may release toxic
mediators leading to adverse outcomes or that the
cause of preterm birth is more complex than has been
suggested by research to date and will require a different
set of measures applied to the intrauterine environment
[23].
Antibiotics in patients with preterm premature
rupture of membranes
The cause of preterm premature rupture of the mem-
branes (PPROM), which occurs in 2 to 4% of all
singleton pregnancies and in a higher proportion of
twin pregnancies, is not known. Most cases of PPROM
occur in otherwise healthy women without identifiable
risk factors. However, ascending choriodecidual infec-
tion has been identified in some cases, although it is not
known whether this is a cause or a consequence of
PPROM. Nevertheless, the use of antibiotics in women
with PPROM has been shown to increase the latency
period, defined as the period between the rupture of
membranes and the onset of labor. A meta-analysis by
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mized trials of the use of antibiotics in patients with
PPROM found a significant increase in the latency period
and a reduction in neonatal sepsis in subjects who
received antibiotic treatment as compared with those
who received placebos. These studies suggested that
broad-spectrum antibiotic coverage (for example, ampi-
cillin-sulbactam) was more effective than a narrow-
spectrum antibiotic (ampicillin). Subsequent trials in
patients with PPROM, including the trial conducted by
the ORACLE Collaborative Group, have confirmed the
efficacy of broad-spectrum antibiotic treatment in
prolonging the latency period, prolonging gestation,
and reducing the incidence of chorioamnionitis and of
neonatal infection and intraventricular hemorrhage [25].
A number of different broad-spectrum antibiotic regi-
mens have been used to treat patients with PPROM.
Although there is no conclusive evidence demonstrating
a single regimen that is superior, a 5-day course of
antibiotic therapy including a macrolide (erythromycin
or azithromycin) is effective [26].
The mechanism of action of the prolongation of the
latency period achieved by antibiotic treatment of
women with PPROM may be more complex than simply
prevention of chorioamniotic infection. A recent study
by Gomez et al. [27] analyzed two amniocentesis
specimens taken 5 days apart in women with PPROM
and found that antibiotic treatment (ceftriaxone, clin-
damycin, and erythromycin) failed to eradicate micro-
bial invasion of the amniotic cavity or eliminate host
inflammatory response. In an evaluation of this study,
Faculty of 1000 member Austin Ugwumadu pointed out
that the findings were consistent with existing evidence
that antibiotics administered to the mother do not reach
therapeutic levels within the fetal compartment to
inhibit common pathogens [28].
Based on the information in two large multicenter
clinical trials [29,30], ACOG recommends a 48-hour
course of ampicillin and erythromycin followed by
5 days of amoxicillin and erythromycin during expectant
management of PPROM remote from term to prolong
pregnancy and to reduce infectious and gestational age-
dependent neonatal morbidity [31]. The use of ampi-
cillin-clavulanic acid is not recommended because of its
association with an increased rate of neonatal necrotiz-
ing enterocolitis [30]. Also, the ACOG recommendation
notes that women with PPROM and who are known
carriers of Group B Streptococcus, and those who give
birth before carrier status can be delineated, should
receive intrapartum prophylaxis (penicillin) to prevent
vertical transmission regardless of earlier treatments. The
guidelines of the Royal College of Obstetricians and
Gynaecologists for the treatment of women with PPROM
differ from those of the ACOG in the antibiotic regimen
recommendation only: erythromycin (250 mg orally
every 6 hours) for 10 days following the diagnosis of
PPROM [32].
Implications for clinical practice
Screening for bacteriuria in prenatal patients is advised.
However, rapid screening tests should not replace urine
culture for detecting asymptomatic bacteriuria. Routine
screening for and treatment of asymptomatic BV are not
indicated. The use of antibiotics to treat women at high
risk of preterm birth or those with idiopathic sponta-
neous preterm labor does not significantly decrease the
incidence of preterm birth and may result in an increased
risk of neonatal developmental abnormalities. This does
not preclude the need for prophylaxis against early-onset
Group B streptococcal disease when indicated. Patients
with preterm premature rupture of membranes should
receive a 7- to 10-day course of antibiotic therapy.
Antibiotic regimens should include a macrolide
(erythromycin or azithromycin) but not ampicillin-
clavulanic acid.
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